Company Monitoring Page for Gilead-Sciences

latest headlines for company on cafepharma

A once-yearly PrEP? Gilead's lenacapavir shows promise as company plots phase 3
Fierce Pharma
Tue, 03/11/25 - 07:10 pm
Tags:
Gilead Sciences, lenacapavir, HUV, PrEP
FDA sets June date for Gilead's twice-yearly HIV PrEP
Pharmaphorum
Wed, 02/19/25 - 09:42 am
Tags:
Gilead Sciences, FDA, PrEP, HIV, lenacapavir
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Fierce Biotech
Tue, 02/18/25 - 11:02 pm
Tags:
Arcus Biosciences, Merck, Gilead Sciences, Welireg, kidney cancer
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
Fierce Pharma
Wed, 02/12/25 - 11:16 am
Tags:
Gilead Sciences, HIV, PrEP, lenacapavir
Gilead Sciences Beats Q4 EPS Forecast
Motley Fool
Tue, 02/11/25 - 09:51 pm
Tags:
Gilead Sciences, earnings
Bristol Myers angles Breyanzi for another blood cancer as it works to close Gilead's CAR-T lead
Fierce Pharma
Mon, 02/10/25 - 10:14 am
Tags:
Bristol Myers Squibb, Breyanzi, CAR-T, marginal zone lymphoma, Gilead Sciences
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy
Fierce Pharma
Thu, 01/16/25 - 11:08 am
Tags:
Gilead Sciences, DOJ, HHS, patents, Truvada, Descovy, legal
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma
Fierce Biotech
Mon, 01/13/25 - 11:03 am
Tags:
Gilead Sciences, JPMHC 2025, LEO Pharma, inflammation
Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
BioSpace
Thu, 12/19/24 - 11:27 am
Tags:
Gilead Sciences, Assembly Bio, funding, hepatitis D
ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases
Fierce Pharma
Thu, 12/12/24 - 11:44 pm
Tags:
ICER, drug pricing, Gilead Sciences, JNJ, Novartis
With Biktarvy patent cliff ahead, Gilead lays out a plan to keep the HIV crown with 7 launches through 2033
Fierce Pharma
Wed, 12/11/24 - 11:40 am
Tags:
Gilead Sciences, Biktarvy, patent cliffs, HIV
Can CAR-T first movers keep pace in a rapidly evolving market?
Pharmaphorum
Wed, 12/11/24 - 10:59 am
Tags:
CAR-T, Gilead Sciences, Novartis
Gilead/Arcellx’s anito-cel’s differentiated safety profile challenges J&J/Legend’s Carvykti
BioSpace
Tue, 12/10/24 - 11:41 am
Tags:
Gilead Sciences, Arcellx, anito-cel, JNJ, Carvykti, Multiple Myeloma
Gilead looks beyond Trodelvy with Tubulis alliance
Pharmaphorum
Tue, 12/3/24 - 09:41 am
Tags:
Gilead Sciences, Tubulis, antibody-drug conjugates
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
Clinical Trials Arena
Sun, 12/1/24 - 11:46 am
Tags:
Gilead Sciences, clinical trials, lenacapavir, HIV, PrEP
Gilead’s Livdelzi shows promise in PBC clinical trial
Clinical Trials Arena
Mon, 11/18/24 - 11:08 am
Tags:
Gilead Sciences, Livdelzi, primary biliary cholangitis, clinical trials
Gilead lays off 72 workers in Seattle, plans to shutter R&D support site
Fierce Biotech
Thu, 11/14/24 - 11:08 pm
Tags:
Gilead Sciences, Seattle, R&D, layoffs
Autolus enters CAR-T race with FDA approval for Aucatzyl
Fierce Pharma
Mon, 11/11/24 - 11:49 am
Tags:
Autolus Therapeutics, CAR-T, FDA, Aucatzyl, Gilead Sciences, Novartis, relapsed or refractory B-cell precursor acute lymphoblastic leukemia
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Fierce Pharma
Thu, 11/7/24 - 11:29 am
Tags:
Gilead Sciences, earnings, Trodelvy, CAR-T
Gilead, Merck say HIV combo could be weekly, oral HIV drug
Pharmaphorum
Mon, 10/21/24 - 09:35 am
Tags:
Gilead Sciences, Merck, HIV, antiretrovirals, clinical trials, islatravir, Sunleca

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.